News stories about Inovio Pharmaceuticals (NASDAQ:INO) have been trending very negative this week, InfoTrie Sentiment reports. InfoTrie ranks the sentiment of media coverage by monitoring more than 6,000 blog and news sources in real-time. The firm ranks coverage of companies on a scale of negative five to five, with scores closest to five being the most favorable. Inovio Pharmaceuticals earned a coverage optimism score of -3.82 on their scale. InfoTrie also assigned media headlines about the biopharmaceutical company an news buzz score of 10 out of 10, meaning that recent media coverage is extremely likely to have an effect on the stock’s share price in the near term.
Here are some of the news stories that may have effected Inovio Pharmaceuticals’ score:
Several research firms recently commented on INO. Stifel Nicolaus reduced their price objective on Inovio Pharmaceuticals from $24.00 to $16.00 in a report on Tuesday, August 11th. Maxim Group upgraded Inovio Pharmaceuticals from a “hold” rating to a “buy” rating and set a $20.00 price objective for the company in a report on Monday. Benchmark reiterated a “buy” rating on shares of Inovio Pharmaceuticals in a report on Tuesday, June 30th. BidaskClub upgraded Inovio Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Wednesday, September 16th. Finally, HC Wainwright reiterated a “hold” rating on shares of Inovio Pharmaceuticals in a report on Wednesday, September 9th. One research analyst has rated the stock with a sell rating, six have assigned a hold rating and four have issued a buy rating to the stock. The company currently has a consensus rating of “Hold” and an average target price of $12.00.
Inovio Pharmaceuticals stock opened at $11.60 on Thursday. The business has a 50-day simple moving average of $13.32 and a two-hundred day simple moving average of $14.56. The company has a market cap of $1.94 billion, a P/E ratio of -193.30 and a beta of 1.09. Inovio Pharmaceuticals has a 52-week low of $1.91 and a 52-week high of $33.79. The company has a quick ratio of 10.06, a current ratio of 10.06 and a debt-to-equity ratio of 0.43.
Inovio Pharmaceuticals (NASDAQ:INO) last released its quarterly earnings results on Monday, August 10th. The biopharmaceutical company reported ($0.83) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.17) by ($0.66). The firm had revenue of $0.20 million for the quarter, compared to the consensus estimate of $2.61 million. Inovio Pharmaceuticals had a net margin of 1,291.83% and a negative return on equity of 52.48%. The company’s revenue for the quarter was up 100.0% compared to the same quarter last year. During the same quarter in the prior year, the firm earned ($0.30) earnings per share. Research analysts anticipate that Inovio Pharmaceuticals will post -0.83 EPS for the current fiscal year.
In other news, insider Laurent Humeau sold 19,467 shares of Inovio Pharmaceuticals stock in a transaction dated Monday, August 10th. The stock was sold at an average price of $19.06, for a total transaction of $371,041.02. Following the transaction, the insider now directly owns 43,966 shares of the company’s stock, valued at approximately $837,991.96. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, CEO Jong Joseph Kim sold 100,000 shares of Inovio Pharmaceuticals stock in a transaction dated Thursday, July 30th. The shares were sold at an average price of $21.13, for a total value of $2,113,000.00. Following the transaction, the chief executive officer now directly owns 1,188,313 shares in the company, valued at $25,109,053.69. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 154,467 shares of company stock worth $3,357,291. Insiders own 4.00% of the company’s stock.
About Inovio Pharmaceuticals
Inovio Pharmaceuticals, Inc, a late-stage biotechnology company, focuses on the discovery, development, and commercialization of DNA-based immunotherapies and vaccines to prevent and treat cancers and infectious diseases. Its SynCon immunotherapy design has the ability to break the immune system’s tolerance of cancerous cells, as well as is intended to facilitate cross-strain protection against known, as well as new unmatched strains of pathogens, such as influenza.
See Also: How does a margin account work?
Receive News & Ratings for Inovio Pharmaceuticals Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Inovio Pharmaceuticals and related companies with MarketBeat.com’s FREE daily email newsletter.